We are live on ! Find out more
IMDZ

Immune Design Corp.
IMDZ

Delisted

IMDZ was delisted on the 1st of April, 2019.

76 hedge funds and large institutions have $101M invested in Immune Design Corp. in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more call options, than puts

Call options by funds: $239K | Put options by funds: $82K

142% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 12

69% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 16

17% more funds holding

Funds holding: 6576 (+11)

31% less capital invested

Capital invested by funds: $147M → $101M (-$45.6M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
76
Holders Change
+11
Holders Change %
+16.92%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
27
Increased
29
Reduced
12
Closed
16
Calls
$239K
Puts
$82K
Net Calls
+$157K
Net Calls Change
-$131K
Name Holding Trade Value Shares
Change
Change in
Stake
EC
1
EcoR1 Capital
California
$13.9M +$19.4M +3,562,600 New
BCPEM
2
Bain Capital Public Equity Management
Massachusetts
$12.9M +$11M +2,017,756 +155%
Franklin Resources
3
Franklin Resources
California
$12.6M +$13.3M +2,450,000 +313%
VVM
4
Versant Venture Management
California
$8.61M
BlackRock
5
BlackRock
New York
$7.29M +$4.53M +830,861 +80%
BI
6
BVF Inc
California
$5.73M +$8M +1,469,800 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.28M +$4.08M +749,883 +124%
PAI
8
ProQuest Associates IV
Florida
$4.82M -$963K -176,886 -13%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$4.62M +$3.74M +686,500 +138%
JP Morgan Chase
10
JP Morgan Chase
New York
$3.58M +$2.24M +411,914 +82%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.95M +$2.72M +500,000 New
MWNA
12
Marshall Wace North America
New York
$1.91M +$2.66M +488,933 New
PAM
13
Panagora Asset Management
Massachusetts
$1.43M +$910K +166,997 +84%
A
14
Abingworth
United Kingdom
$1.37M
DCM
15
DAFNA Capital Management
California
$1.28M +$1.79M +328,500 New
Northern Trust
16
Northern Trust
Illinois
$1.26M +$791K +145,182 +82%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.11M +$878K +161,168 +130%
ACP
18
Acuta Capital Partners
California
$1.07M +$1.49M +274,100 New
State Street
19
State Street
Massachusetts
$942K +$110K +20,188 +9%
Two Sigma Investments
20
Two Sigma Investments
New York
$850K +$1.1M +201,441 +1,223%
WMSA
21
Weiss Multi-Strategy Advisers
New York
$659K +$921K +169,034 New
Victory Capital Management
22
Victory Capital Management
Texas
$613K -$10.4M -1,903,115 -92%
BBA
23
Baker Bros. Advisors
New York
$581K
Wells Fargo
24
Wells Fargo
California
$562K -$168K -30,924 -18%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$476K +$269K +49,464 +68%

IMDZ Hedge Fund Activity: Q4 2017 in Review

76 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q4 2017, worth a combined $101M — down 31% from $147M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new IMDZ positions and 16 closed out — a net gain of 11 holders — while 29 added to existing stakes and 12 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $19.4M. The largest seller was Victory Capital Management, cutting an estimated $10.4M.

  • 76 institutional investors held Immune Design Corp. (IMDZ) as of Q4 2017, up from 65 in Q3 2017.
  • Funds reported $101M of Immune Design Corp. stock for Q4 2017, down 31% quarter-over-quarter.
  • 27 funds opened new Immune Design Corp. positions in Q4 2017 and 16 closed out, a net change of +11 holders.
  • The largest Immune Design Corp. buyer in Q4 2017 was EcoR1 Capital, an estimated $19.4M added.
  • The largest Immune Design Corp. seller in Q4 2017 was Victory Capital Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2017.